New Hampshire Trust Sells 65 Shares of Stryker Co. (NYSE:SYK)

New Hampshire Trust cut its stake in shares of Stryker Co. (NYSE:SYK) by 4.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,415 shares of the medical technology company’s stock after selling 65 shares during the quarter. New Hampshire Trust’s holdings in Stryker were worth $509,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sky Investment Group LLC increased its stake in shares of Stryker by 0.6% in the fourth quarter. Sky Investment Group LLC now owns 15,204 shares of the medical technology company’s stock worth $5,474,000 after purchasing an additional 85 shares in the last quarter. Union Savings Bank increased its stake in Stryker by 1.0% in the 4th quarter. Union Savings Bank now owns 3,162 shares of the medical technology company’s stock worth $1,138,000 after buying an additional 31 shares in the last quarter. Zhang Financial LLC lifted its position in shares of Stryker by 55.0% in the fourth quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock valued at $41,366,000 after acquiring an additional 40,784 shares in the last quarter. Shore Point Advisors LLC bought a new position in shares of Stryker in the fourth quarter worth about $343,000. Finally, Purus Wealth Management LLC grew its position in shares of Stryker by 6.6% during the fourth quarter. Purus Wealth Management LLC now owns 714 shares of the medical technology company’s stock worth $257,000 after purchasing an additional 44 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 0.6 %

Shares of NYSE SYK opened at $383.91 on Tuesday. Stryker Co. has a 1 year low of $307.23 and a 1 year high of $398.20. The firm has a 50-day simple moving average of $375.51 and a two-hundred day simple moving average of $359.17. The company has a market cap of $146.35 billion, a P/E ratio of 41.15, a PEG ratio of 2.63 and a beta of 0.95. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The company had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. During the same quarter in the previous year, the business earned $2.46 EPS. Stryker’s revenue was up 11.9% compared to the same quarter last year. Research analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.88%. The ex-dividend date is Tuesday, December 31st. This is an increase from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio (DPR) is currently 36.01%.

Analysts Set New Price Targets

Several research firms have weighed in on SYK. JPMorgan Chase & Co. upped their price target on Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Barclays upped their target price on shares of Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a research report on Thursday, October 31st. BTIG Research boosted their price target on shares of Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Royal Bank of Canada restated an “outperform” rating and set a $425.00 price objective on shares of Stryker in a research report on Tuesday, January 7th. Finally, Evercore ISI boosted their target price on Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $405.80.

Insider Activity at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 5.50% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.